A photo of Michael Grimley.

Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics

513-803-1969

Board Certified

"I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family."

My Biography & Research

Biography

I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.

As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

My research involves finding treatments for and prevention of viral infections in immunocompromised patients.

When I’m not treating patients or involved in research, I enjoy spending time with my family.

Clinical Interests

Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Immune Deficiencies and Histiocytosis

Research Divisions

Bone Marrow Transplantation, Cancer and Blood Diseases

My Education

MD: Emory University School of Medicine, Atlanta, GA, 1992.

Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.

Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.

Certification: General Pediatrics, Pediatric Hematology/Oncology.

Licenses: Ohio, Texas.

My Publications

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al. Blood Advances. 2020; 4:5745-5754.

Non-Tuberculous Mycobacterial Infection in Hematopoietic Cell Transplant. Sabulski, A; Davies, SM; Paulsen, G; Kumar, A; Grimley, M; Chandra, S. Journal of Clinical Immunology. 2020; 40:1171-1175.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al. Blood Advances. 2020; 4:3252-3257.

Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa. Khandelwal, P; Yeh, RF; Yu, L; Lane, A; Dandoy, CE; El- Bietar, J; Davies, SM; Grimley, MS. Transplantation. 2020; Publish Ahead of Print.

Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al. Pediatric Transplantation. 2020; 24.

EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al. Pediatric Blood and Cancer. 2020; 67.

High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR. Blood Advances. 2020; 4:717-727.

Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-gamma Responsive Pathway. Haake, K; Neehus, A; Buchegger, T; Kuehnel, MP; Blank, P; Philipp, F; Oleaga-Quintas, C; Schulz, A; Grimley, M; Goethe, R; et al. Cells. 2020; 9:483-483.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.